The invention relates to the use of an IL18-BP isoform that does not bind toIL18, or of an agonist thereof, for treatment or prevention of a neurologicaland/or inflammatory disease. Preferred isoforms for use in the frame of thepresent invention include IL-18BPb and IL-18BPd.